^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    1d
    ORIGIN2: Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Swiss Cancer Institute | Trial completion date: Mar 2029 --> Jul 2029 | Initiation date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2028
    Trial completion date • Trial initiation date • Trial primary completion date • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    gemcitabine • Yidafan (ivonescimab)
    2d
    Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=550, Recruiting, Pfizer | N=182 --> 550
    Enrollment change • Trial initiation date
    |
    Tecentriq (atezolizumab)
    2d
    C6461013: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Pfizer | N=78 --> 138
    Enrollment change • Trial initiation date
    |
    Yervoy (ipilimumab)
    2d
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer | N=53 --> 162
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    2d
    Pregonda: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=151, Active, not recruiting, Genentech, Inc. | Trial completion date: Apr 2027 --> Jan 2027 | Trial primary completion date: Feb 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    2d
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (clinicaltrials.gov)
    P3, N=574, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)
    5d
    A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Datroway (datopotamab deruxtecan-dlnk) • Yidafan (ivonescimab)
    5d
    A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yidafan (ivonescimab)
    7d
    C6461013: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Pfizer
    New P1/2 trial
    |
    Yervoy (ipilimumab)
    7d
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Pfizer
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    8d
    Oncologic strategies and options for the management of metastatic thymic carcinoma. (PubMed, Mediastinum)
    Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.
    Review • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin)
    |
    KIT mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • bintrafusp alfa (M7824) • Yidafan (ivonescimab)
    9d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer (clinicaltrials.gov)
    P2/3, N=840, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab)